Efficacy of Ketamine for Improvement in Postoperative Pain Control After Spinal Fusion for Idiopathic Scoliosis

Sponsor
Albany Medical College (Other)
Overall Status
Unknown status
CT.gov ID
NCT02651324
Collaborator
(none)
50
1
2
55
0.9

Study Details

Study Description

Brief Summary

This study hypothesizes that the addition of a low-dose ketamine infusion to usual post-operative pain management will improve pain control as evidenced by an improvement in post-operative pain scores for patients undergoing spinal fusion for idiopathic scoliosis.

Condition or Disease Intervention/Treatment Phase
Phase 4

Detailed Description

After consenting, patients will be randomized by the pharmacy. In the operating room patients will receive ketamine/placebo 0.5mg/kg bolus prior to the surgical incision, followed by ketamine/placebo 0.2mg/kg continuous infusion up to 48hours. All the patients will also receive 15mg/k IV acetaminophen at the end of the surgery, followed by every 6hr for 48hrs. Rest of the pain regimen will be the usual post-operative pain management for spinal fusion for idiopathic scoliosis, which includes morphine PCA, IV ketorolac from POD 1, and flexaril from POD 1.

All the patients and parents will fill out a survey at 0hr, 24hr and 48hr grading their level of satisfaction with the post-operative pain.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Care Provider, Investigator)
Primary Purpose:
Treatment
Official Title:
A Prospective, Randomized, Double-Blind, Controlled Trial Evaluating the Efficacy of Ketamine for Improvement in Postoperative Pain Control After Spinal Fusion for Idiopathic Scoliosis
Actual Study Start Date :
May 1, 2013
Anticipated Primary Completion Date :
Dec 1, 2017
Anticipated Study Completion Date :
Dec 1, 2017

Arms and Interventions

Arm Intervention/Treatment
Experimental: Treatment Group

A ketamine bolus of 0.5mg/kg will be given and then the ketamine infusion of 0.2 mg/kg/hr will be initiated prior to incision. Intra-operative opioids will be at the discretion of the attending anesthesiologist. Postoperative management will include continuation of the study drug as well as a standardized morphine patient-controlled analgesia (PCA) and acetaminophen 15 mg/kg IV every 6 hours. On postoperative day 1, patients are started on ketorolac 0.5 mg/kg up to 15 mg IV q8h. On postoperative day 2 they are transitioned to ibuprofen 10 mg/kg up to 600 mg. The ketamine infusion will continue for 48 hours post operatively at which point the PCA is discontinued and patients are transitioned to oral pain medications (Roxicet or Lortab and Flexeril) as per the current protocol.

Drug: Ketamine

Placebo Comparator: Placebo

A placebo (saline) will be given in place of ketamine

Other: Placebo
Other Names:
  • Saline
  • Outcome Measures

    Primary Outcome Measures

    1. Patient Satisfaction [Through study completion, 48 hours]

      All the patients and parent will fill out a survey grading their level of satisfaction with their post-operative pain management

    Secondary Outcome Measures

    1. Pain Score [Through study completion 48 hours]

      Pain scores will be collected from the nursing sheet

    2. Opioid Use [Through study completion, 48 hours]

      Total Morphine consumption will be collected from PCA data

    3. Length of Stay [Through study completion, 48 hours]

      Length of hospital stay from surgery to discharge

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • ASA I, II, III

    • Presenting for spinal fusion for idiopathic scoliosis

    • English-speaking and able to give assent

    Exclusion Criteria:
    • Any contraindication to ketamine

    • Previous spinal surgery

    • Opioid dependence

    • Chronic pain condition

    • Significant developmental delay

    • Pregnancy

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Albany Medical Center Albany New York United States 12208

    Sponsors and Collaborators

    • Albany Medical College

    Investigators

    • Principal Investigator: Farzana Afroze, MD, Albany Medical College

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Farzana Afroze, Anesthesiologist, Albany Medical College
    ClinicalTrials.gov Identifier:
    NCT02651324
    Other Study ID Numbers:
    • 3497
    First Posted:
    Jan 11, 2016
    Last Update Posted:
    Jul 2, 2017
    Last Verified:
    Jun 1, 2017
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 2, 2017